Xueying Chen1, Ahmed Bakillah2, Liye Zhou2, Xiaoyue Pan2, Florian Hoepfner3, Marrit Jacob3, Xian-Cheng Jiang4, Jason Lazar5, Axel Schlitt6, M Mahmood Hussain7. 1. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA; Institute of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, PR China. 2. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA. 3. Department of Medicine III, University Clinic Halle, Germany. 4. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA; VA New York Harbor Healthcare System, Brooklyn, NY 11209, USA. 5. Division of Cardiovascular Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. 6. Department of Medicine III, University Clinic Halle, Germany; Paracelsus-Harz-Clinic Bad Suderode, Quedlinburg, Germany. 7. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA; VA New York Harbor Healthcare System, Brooklyn, NY 11209, USA; Department of Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY, USA. Electronic address: Mahmood.hussain@downstate.edu.
Abstract
AIMS/HYPOTHESIS: Recent studies have suggested that determination of HDL function may be more informative than its concentration in predicting its protective role in coronary artery disease (CAD). Apolipoprotein AI (apoAI), the major protein of HDL, is nitrosylated in vivo to nitrated apoAI (NT-apoAI) that might cause dysfunction. We hypothesized that NT-apoAI/apoAI ratio might be associated with diabetes mellitus (DM) in CAD patients. METHODS: We measured plasma NT-apoAI and apoAI levels in 777 patients with coronary artery disease (CAD) by ELISA. Further, we measured plasma cholesterol efflux potential in subjects with similar apoAI but different NT-apoAI levels. RESULTS: We found that median NT-apoAI/apoAI ratio was significantly higher in diabetes mellitus (DM) (n = 327) versus non-diabetic patients (n = 450). Further analysis indicated that DM, thiobarbituric acid-reactive substances and C-reactive protein levels were independent predictors of higher NT-apoAI/apoAI ratio. There was negative correlation between NT-apoAI/apoAI and use of anti-platelet and lipid lowering drugs. The cholesterol efflux capacity of plasma from 67 individuals with differing NT-apoAI but similar apoAI levels from macrophages in vitro was negatively correlated with NT-apoAI/apoAI ratio. CONCLUSIONS: Higher NT-apoAI/apoAI ratio is significantly associated with DM in this relatively large German cohort with CAD and may contribute to associated complications by reducing cholesterol efflux capacity.
AIMS/HYPOTHESIS: Recent studies have suggested that determination of HDL function may be more informative than its concentration in predicting its protective role in coronary artery disease (CAD). Apolipoprotein AI (apoAI), the major protein of HDL, is nitrosylated in vivo to nitrated apoAI (NT-apoAI) that might cause dysfunction. We hypothesized that NT-apoAI/apoAI ratio might be associated with diabetes mellitus (DM) in CAD patients. METHODS: We measured plasma NT-apoAI and apoAI levels in 777 patients with coronary artery disease (CAD) by ELISA. Further, we measured plasma cholesterol efflux potential in subjects with similar apoAI but different NT-apoAI levels. RESULTS: We found that median NT-apoAI/apoAI ratio was significantly higher in diabetes mellitus (DM) (n = 327) versus non-diabeticpatients (n = 450). Further analysis indicated that DM, thiobarbituric acid-reactive substances and C-reactive protein levels were independent predictors of higher NT-apoAI/apoAI ratio. There was negative correlation between NT-apoAI/apoAI and use of anti-platelet and lipid lowering drugs. The cholesterol efflux capacity of plasma from 67 individuals with differing NT-apoAI but similar apoAI levels from macrophages in vitro was negatively correlated with NT-apoAI/apoAI ratio. CONCLUSIONS: Higher NT-apoAI/apoAI ratio is significantly associated with DM in this relatively large German cohort with CAD and may contribute to associated complications by reducing cholesterol efflux capacity.
Authors: Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Sarah Martin; Rukhsana Sultana; Cesare Mancuso; Michael Paul Murphy; Elizabeth Head; D Allan Butterfield Journal: Pharmacol Res Date: 2010-12-27 Impact factor: 7.658
Authors: Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader Journal: N Engl J Med Date: 2011-01-13 Impact factor: 91.245
Authors: Antonio Ceriello; Claudio Taboga; Laura Tonutti; Lisa Quagliaro; Ludovica Piconi; Bruno Bais; Roberto Da Ros; Enrico Motz Journal: Circulation Date: 2002-09-03 Impact factor: 29.690